Skip to main content
Terug
Watch Compare

Aligos Therapeutics, Inc.

Datakwaliteit: 100%
ALGS
Nasdaq Manufacturing Chemicals
€ 7,97
▼ € 0,02 (-0,25%)
Marktkapitalisatie: 49,32 M
Prijs
€ 7,97
Marktkapitalisatie
49,32 M
Dagbereik
€ 7,77 — € 8,06
52-Weeksbereik
€ 3,76 — € 13,69
Volume
10.996
Openen € 7,96
50D / 200D Gem.
€ 7,27
9,60% above
50D / 200D Gem.
€ 8,68
8,16% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -82,50 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-39,46%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-27,86%
Boven sectorgemiddelde (-53,47%)
ROIC-68,75%
Net Margin-1106,72%
Op. Margin-4024,93%

Veiligheid

Debt / Equity
N/A
Current Ratio4,70
Interest Coverage-39,99

Waardering

PE (TTM)
-2,04
Onder sectorgemiddelde (-1,47)
P/B Ratio0,69
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,0 -1,5
P/B 0,7 1,6
ROE % -27,9 -53,5
Net Margin % -1106,7 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -39,46% Revenue Growth (3Y) -40,58%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,19 M Net Income (TTM) -24,19 M
ROE -27,86% ROA -19,79%
Gross Margin N/A Operating Margin -4024,93%
Net Margin -1106,72% Free Cash Flow (TTM) -82,50 M
ROIC -68,75% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,70
Interest Coverage -39,99 Asset Turnover 0,02
Working Capital 81,45 M Tangible Book Value 71,83 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,04 Forward P/E N/A
P/B Ratio 0,69 P/S Ratio 22,56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -167,29%
Market Cap 49,32 M Enterprise Value 7,37 M
Per Share
EPS (Diluted TTM) -2,45 Revenue / Share 0,35
FCF / Share -13,33 OCF / Share -13,33
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 341,02%
SBC-Adj. FCF -88,13 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,19 M 3,61 M 6,19 M 0,0 0,0
Net Income -24,19 M -131,21 M -87,68 M -96,05 M -128,33 M
EPS (Diluted) -2,45 -20,94 -1,36 — —
Gross Profit — — — — —
Operating Income -87,99 M -89,15 M -88,13 M -97,58 M -128,32 M
EBITDA — — — — —
R&D Expenses 69,45 M 70,27 M 73,04 M 85,08 M 104,15 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 2,20 M 1,70 M 4,30 M — —
Income Tax 314.000,0 331.000,0 795.000,0 106.000,0 143.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 88,53 M 70,09 M 151,53 M 146,69 M 235,37 M
Total Liabilities 34,99 M 99,07 M 59,45 M 42,79 M 50,64 M
Shareholders' Equity 53,55 M -28,97 M 92,08 M 103,90 M 184,73 M
Total Debt — — — — —
Cash & Equivalents 18,30 M 37,00 M 135,70 M 81,35 M 186,82 M
Current Assets 82,86 M 62,14 M 141,08 M 133,55 M 204,42 M
Current Liabilities 21,23 M 21,74 M 23,91 M 33,13 M 38,96 M